Exicure, Inc.

Stage 4 · Declining · week 34

As of Oct 22, 2026, Exicure is in Stage 4, the downtrend phase, now in week 34 (since Feb 20, 2026). It closed at $1.13, 84.5% below its 52-week high and below its 200-day average, which is falling.

Exicure, Inc. does not have significant operations. More about the company

$1.13

+13.00% today

$7.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is XCUR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 25w

S4 16w

S2 15w

S4 23w

S4 35w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 1w → S4 25w → S1 10w → S4 16w → S1 11w → S2 15w → S3 6w → S2 8w → S3 4w → S4 23w → S1 11w → S4 35w current

Total tracked: 165 weeks across 12 stage runs.

XCUR among Biotechnology450th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…450	XCURExicure, Inc.	Stage 4 · wk 34	13	−8.9%

vs 52W High

-84.5%

$1.00 lo$7.29 hi

84.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 34

1w13w26w

Week 34, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-60.5%

200 DMA: $2.86 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

10.84x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-8.9%

-35.8%

-69.0%

YTD

-79.7%

-75.7%

Scan Membership

Breakout Watch

Latest: 2025-04-04

5 appearances in last 60 days. First seen: 2019-11-29.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 34 · Vol 10.84x

2026-10-21S4

Wk 34 · Vol 1.80x

2026-10-20S4

Wk 34 · Vol 1.13x

2026-10-19S4

Wk 34 · Vol 1.82x

2026-10-16S4

Wk 34 · Vol 0.85x

2026-10-15S4

Wk 33 · Vol 0.53x

2026-10-14S4

Wk 33 · Vol 0.72x

2026-10-13S4

Wk 33 · Vol 0.69x

2026-10-12S4

Wk 33 · Vol 0.38x

2026-10-09S4

Wk 33 · Vol 9.04x

2026-10-08S4

Wk 32 · Vol 0.42x

2026-10-07S4

Wk 32 · Vol 0.26x

Moving averages & range

50 DMA

$1.23

200 DMA

$2.86

52W High

$7.29

52W Low

$1.00

5D Low

$1.00

Resistance levels (recent highs)

20d High

$1.24

60d High

$1.60

120d High

$3.40

250d High

$7.29

Next resistance

+9.3%

to 20d High

ROE

-168.4%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 7.4

Exicure: quick answers

What stage is Exicure in?

As of Oct 22, 2026, Exicure (XCUR) is in Stage 4, the downtrend phase. It entered Stage 4 on Feb 20, 2026 and is in week 34. What the four stages mean

Is Exicure in an uptrend?

No. Exicure is in a Stage 4 downtrend. It trades 60.5% below its 200-day average, which is falling.

How far is Exicure from its 52-week high?

Exicure closed at $1.13 on Oct 22, 2026, 84.5% below its 52-week high of $7.29. Its 52-week low is $1.00.

How has Exicure performed over the past year?

As of Oct 22, 2026, Exicure is down 75.7% over the past year and down 79.7% so far in 2026.

Which sector and industry is Exicure in?

Exicure is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.